Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma Interventions:   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Venetoclax Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials